Recurrent or metastatic head and neck squamous cell carcinoma: the decisions you may face

Cancer page →Second-opinion finder →

6 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Advanced, first line

First line, combined positive score 1 or more

One path named

Pembrolizumab alone for indolent disease, especially with a score of 20 or more; pembrolizumab with platinum and fluorouracil for bulky or symptomatic disease (KEYNOTE-048).

Guideline

NCCN · Category 1

The path, in plain words

PembrolizumabApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.

Also referenced:PD-L1 expression testing (22C3, SP142, SP263)Combined positive score (CPS)

The evidence behind it

KEYNOTE-048 Phase 3 NCT02358031 2019882 peopleevidence 95
Tests Pembrolizumab
Untreated recurrent or metastatic HNSCC: pembrolizumab alone, pembrolizumab + platinum/5-FU, or cetuximab + platinum/5-FU (EXTREME)
OS 14.9 vs 10.7 months (CPS ≥20, monotherapy); 13.0 vs 10.7 (all, with chemotherapy).
Overall survival, CPS ≥20, pembrolizumab monotherapy (months): Pembrolizumab 14.9 vs Cetuximab + chemotherapy 10.7 · HR 0.61 · source

The main trade-offs on record

Pembrolizumab all recorded rates →

Side effect	Any grade	Grade 3+
Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients	8%	-
Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients	3.4%	-
Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients	1.7%	-
Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients	0.7%	-

No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision

Is Pembrolizumab the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in KEYNOTE-048, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
Which side effects of Pembrolizumab are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (first line, combined positive score 1 or more), which of the standard options do you recommend and why?
Why: Guideline options include: Pembrolizumab alone for indolent disease, especially with a score of 20 or more; pembrolizumab with platinum and fluorouracil for bulky or symptomatic disease (KEYNOTE-048).
Am I a candidate for Pembrolizumab, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of KEYNOTE-048 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Advanced, first line

First line, combined positive score under 1 or immunotherapy unsuitable

6 optionsCompare side by side →

Pembrolizumab with platinum-fluorouracil, or cetuximab with platinum-fluorouracil (EXTREME) or with docetaxel and platinum (TPExtreme).

Guideline

NCCN · Category 1

The options, in plain words

PembrolizumabApprovedMonoclonal antibody (anti-PD-1)

CisplatinApprovedCytotoxic chemotherapy (platinum)

Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.

CarboplatinApprovedCytotoxic chemotherapy (platinum)

Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.

Fluorouracil (5-FU)ApprovedFluoropyrimidine antimetabolite

The 1957 chemotherapy that remains the backbone of treatment for bowel, stomach, pancreatic, anal, head and neck and breast cancers, and as a cream for skin precancers.

CetuximabApprovedMonoclonal antibody (anti-EGFR)

Cetuximab is a chimeric antibody that blocks the EGFR growth receptor. It is used with FOLFIRI or FOLFOX in RAS wild-type, left-sided bowel cancer, with encorafenib in BRAF V600E disease, with KRAS G12C inhibitors, and with radiation or chemotherapy in head and neck cancer; RAS-mutant tumours gain nothing and may be harmed, so RAS testing comes first.

DocetaxelApprovedCytotoxic chemotherapy (taxane)

The first chemotherapy to extend life in prostate cancer (2004), now part of triplet therapy at first metastatic diagnosis.

The evidence behind it

EXTREME Phase 3 NCT00122460 2008442 peopleevidence 88
Untreated recurrent or metastatic HNSCC: cetuximab + platinum/5-FU vs platinum/5-FU
OS 10.1 vs 7.4 months; HR 0.80.
Overall survival (months): Cetuximab + chemotherapy 10.1 vs Chemotherapy 7.4 · HR 0.8 · source
KEYNOTE-048 Phase 3 NCT02358031 2019882 peopleevidence 95
Tests Pembrolizumab
Untreated recurrent or metastatic HNSCC: pembrolizumab alone, pembrolizumab + platinum/5-FU, or cetuximab + platinum/5-FU (EXTREME)
OS 14.9 vs 10.7 months (CPS ≥20, monotherapy); 13.0 vs 10.7 (all, with chemotherapy).
Overall survival, CPS ≥20, pembrolizumab monotherapy (months): Pembrolizumab 14.9 vs Cetuximab + chemotherapy 10.7 · HR 0.61 · source

The main trade-offs on record

Pembrolizumab all recorded rates →

Side effect	Any grade	Grade 3+
Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients	8%	-
Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients	3.4%	-
Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients	1.7%	-
Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients	0.7%	-

No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Cisplatin all recorded rates →

Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).

Carboplatin all recorded rates →

Dose by Calvert formula using GFR (see the calculators).

Fluorouracil (5-FU)all recorded rates →

Capecitabine: take within 30 minutes after a meal. DPD deficiency (DPYD variants) causes severe toxicity: pre-treatment genotyping is recommended in Europe.
Capecitabine: reduce to 75% for CrCl 30-50; contraindicated below 30.

Docetaxel all recorded rates →

Do not give if bilirubin above ULN, or AST/ALT above 1.5 x ULN with alkaline phosphatase above 2.5 x ULN (treatment-related deaths).

Questions to ask about this decision

Between Pembrolizumab, Cisplatin, Carboplatin and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in EXTREME and KEYNOTE-048, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
Which side effects of Pembrolizumab are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (first line, combined positive score under 1 or immunotherapy unsuitable), which of the standard options do you recommend and why?
Why: Guideline options include: Pembrolizumab with platinum-fluorouracil, or cetuximab with platinum-fluorouracil (EXTREME) or with docetaxel and platinum (TPExtreme).
Am I a candidate for Pembrolizumab, Cisplatin, Carboplatin or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of EXTREME and KEYNOTE-048 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Second line

After platinum and immunotherapy

5 optionsCompare side by side →

Cetuximab, docetaxel, paclitaxel or methotrexate as single agents; nivolumab or pembrolizumab if not given before (CheckMate 141); clinical trials.

Guideline

NCCN · Category 1 (nivolumab, pembrolizumab)

The options, in plain words

NivolumabApprovedMonoclonal antibody (anti-PD-1)

Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.

CetuximabApprovedMonoclonal antibody (anti-EGFR)

DocetaxelApprovedCytotoxic chemotherapy (taxane)

The first chemotherapy to extend life in prostate cancer (2004), now part of triplet therapy at first metastatic diagnosis.

Paclitaxel / nab-paclitaxelApprovedCytotoxic chemotherapy (taxane)

A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.

MethotrexateApprovedAntifolate (DHFR inhibitor)

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

The evidence behind it

CheckMate 141 Phase 3 NCT02105636 2016361 peopleevidence 93
Tests Nivolumab
Platinum-refractory recurrent or metastatic HNSCC: nivolumab vs investigator's choice (methotrexate, docetaxel, or cetuximab)
OS 7.5 vs 5.1 months; HR 0.70.
Overall survival (months): Nivolumab 7.5 vs Investigator's choice 5.1 · HR 0.7 · source

The main trade-offs on record

Nivolumab all recorded rates →

Side effect	Any grade	Grade 3+
Colitis with ipilimumab (1+3 mg/kg) · Monotherapy pooled unless stated	25%	14.4%
Hepatitis with ipilimumab · Monotherapy pooled unless stated	15%	13.4%
Colitis · Monotherapy pooled unless stated	2.9%	1.7%
Hepatitis · Monotherapy pooled unless stated	1.8%	1.5%

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Docetaxel all recorded rates →

Do not give if bilirubin above ULN, or AST/ALT above 1.5 x ULN with alkaline phosphatase above 2.5 x ULN (treatment-related deaths).

Methotrexate all recorded rates →

High-dose methotrexate requires normal renal function, hydration, urine alkalinisation and leucovorin rescue with level monitoring.

Questions to ask about this decision

Between Nivolumab, Cetuximab, Docetaxel and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in CheckMate 141, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
Which side effects of Nivolumab are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (after platinum and immunotherapy), which of the standard options do you recommend and why?
Why: Guideline options include: Cetuximab, docetaxel, paclitaxel or methotrexate as single agents; nivolumab or pembrolizumab if not given before (CheckMate 141); clinical trials.
Am I a candidate for Nivolumab, Cetuximab, Docetaxel or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of CheckMate 141 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Second line

Locoregional recurrence

4 options

Salvage surgery where resectable; re-irradiation with intensity-modulated or stereotactic techniques in selected patients; cetuximab sarotalocan photoimmunotherapy in Japan.

Guideline

ESMO-MCBS · 2 (cetuximab sarotalocan, single-arm)

The options, in plain words

IMRT / IGRT (modern external beam)Standard of care

IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.

Conformal dose, fewer side effects
Hypofractionation saves visits

SBRT / SABR (stereotactic radiotherapy)Standard of care

Stereotactic body radiotherapy converges multiple beams with sub-millimetre accuracy to deliver tumour-destroying doses in one to five outpatient sessions, doing the job of surgery for inoperable early lung cancer and for metastases in liver, spine and brain. Tumour size and location limit its use, and late toxicity is a concern near the central airways.

Ablative doses with minimal recovery
Outpatient

Cetuximab sarotalocanApprovedPhotoimmunotherapy conjugate (anti-EGFR antibody-IR700 dye)

Cetuximab sarotalocan is an EGFR antibody carrying a light-activated dye: after infusion, a red laser is shone on the tumour and the cells burst. It has been approved in Japan since 2020.

Photoimmunotherapy & photodynamic therapyApproved

An antibody carries a light-sensitive dye to the tumour; shining near-infrared light then bursts the cells.

Highly selective, repeatable
Immunogenic

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

IMRT / IGRT (modern external beam)

Low-dose bath to normal tissue
Motion management

SBRT / SABR (stereotactic radiotherapy)

Size and location limits
Late toxicity near central airways

Photoimmunotherapy & photodynamic therapy

Light penetration limits to accessible tumours

Questions to ask about this decision

Between IMRT / IGRT (modern external beam), SBRT / SABR (stereotactic radiotherapy), Cetuximab sarotalocan and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (locoregional recurrence), which of the standard options do you recommend and why?
Why: Guideline options include: Salvage surgery where resectable; re-irradiation with intensity-modulated or stereotactic techniques in selected patients; cetuximab sarotalocan photoimmunotherapy in Japan.
Am I a candidate for Cetuximab sarotalocan, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Resource-limited settings

One path named

Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS).

The path, in plain words

MethotrexateApprovedAntifolate (DHFR inhibitor)

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

The evidence behind it

Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)Phase 3 2020422 peopleevidence 83
Tests Methotrexate
Recurrent, metastatic or inoperable head and neck carcinoma, palliative intent: oral methotrexate 15 mg/m2 weekly plus celecoxib 200 mg twice daily vs intravenous cisplatin
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
Median OS 7.5 vs 6.1 months, HR 0.773; grade 3+ adverse events 19% vs 30%.
Median overall survival (months): Oral metronomic (methotrexate + celecoxib) 7.5 (n=213) vs IV cisplatin 6.1 (n=209) · HR 0.773 · source
Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)Phase 3 2023151 peopleevidence 81
Tests Methotrexate
Recurrent or newly diagnosed advanced head and neck squamous cell carcinoma, palliative intent: triple oral metronomic chemotherapy with or without nivolumab 20 mg every 3 weeks
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
1-year OS 43.4% vs 16.3%; median OS 10.1 vs 6.7 months; HR 0.545.
Overall survival at 1 year (%): Metronomic chemotherapy + low-dose nivolumab 43.4 (n=76) vs Metronomic chemotherapy 16.3 (n=75) · HR 0.545 · source
METRO PLUS (Tata Memorial Centre, Varanasi)Phase 3 2026238 peopleevidence 82
Tests Methotrexate
Advanced unresectable head and neck cancer: paclitaxel-carboplatin with or without oral metronomic chemotherapy
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
Median OS 10 vs 5 months, HR 0.54.
Median overall survival (months): Paclitaxel-carboplatin + oral metronomic chemotherapy 10 (n=119) vs Paclitaxel-carboplatin 5 (n=119) · HR 0.54 · source

The main trade-offs on record

Methotrexate all recorded rates →

High-dose methotrexate requires normal renal function, hydration, urine alkalinisation and leucovorin rescue with level monitoring.

Questions to ask about this decision

Is Methotrexate the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) and Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (resource-limited settings), which of the standard options do you recommend and why?
Why: Guideline options include: Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS).
Am I a candidate for Methotrexate, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) and Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Symptom control

One path named

Palliative radiotherapy for bleeding, pain or airway compromise; early involvement of palliative care, nutrition and speech and swallowing teams.

The path, in plain words

Palliative radiotherapyStandard of care

Short courses of radiation, often a single treatment, to relieve pain from bone metastases, stop bleeding, open blocked airways or protect the spinal cord. Among the most cost-effective treatments in cancer.

Single fraction as good as multiple for bone pain
Fast, cheap, widely available
Effective for bleeding, obstruction, cord compression

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Palliative radiotherapy

Underuse of single fractions and overuse of long courses
Pain flare in ~30%
Retreatment limits with prior high doses

Questions to ask about this decision

Is Palliative radiotherapy the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (symptom control), which of the standard options do you recommend and why?
Why: Guideline options include: Palliative radiotherapy for bleeding, pain or airway compromise; early involvement of palliative care, nutrition and speech and swallowing teams.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.